Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Dupilumab/ustekinumab

Treatment failure: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wang H, et al. 1546 Developing personalized therapy for Netherton syndrome based on skin gene expression analysis, cell profiling and inflammatory pathway characterization. Journal of Investigative Dermatology 143 (Suppl.): S265 abstr. 1546, No. 5, May 2023. Available from: URL: http://doi.org/10.1016/j.jid.2023.03.1564 [abstract] Wang H, et al. 1546 Developing personalized therapy for Netherton syndrome based on skin gene expression analysis, cell profiling and inflammatory pathway characterization. Journal of Investigative Dermatology 143 (Suppl.): S265 abstr. 1546, No. 5, May 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​jid.​2023.​03.​1564 [abstract]
Metadaten
Titel
Dupilumab/ustekinumab
Treatment failure: case report
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-38408-7

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Brigatinib

Case report

Antituberculars

Case report

Heparin

Case report

Amenamevir